News

  An international and multidisciplinary team, led by researchers from the Champalimaud Foundation, in Lisbon, has developed an artificial intelligence algorithm that improves the reliability of prostate cancer detection based solely on magnetic resonance imaging...

Prostate cancer is the second most commonly diagnosed cancer in men. Conventional screening relies on prostate specific antigen (PSA) levels in the blood, which can indicate prostate abnormalities but lacks specificity. Clinical examination and ultrasound also have...

The ProCAncer-I project aims to revolutionize prostate cancer diagnosis and treatment through the power of artificial intelligence and advanced imaging. By creating a large, federated database of prostate MRI scans and clinical data, the project enables the...

ProCAncer-I results | Prof. Daniele Regge on clinical validation In this video, we present the results of the clinical validation of AI models that were developed during the ProCAncer-i Project. Clinical validation is a critical step to ensure that AI tools not only...

ProCAncer-I results | Prof. Papanikolaou on Prostanet including PI-QUAL Study and tools Since its inception, the ProCAncer-I project has aimed to establish a robust, ethically compliant AI platform—ProstateNet—to revolutionize prostate cancer (PCa) care through...

In the following AI-generated audio file, ProCAncer-I achievements are described  in a simple way. Since its inception, the ProCAncer-I project has been on a mission to transform prostate cancer (PCa) care through advanced AI and ethically compliant data platforms. At...

The role of artificial intelligence (AI) in healthcare is expanding rapidly, but trust remains a crucial barrier to its widespread adoption. The following AI-generated audio file, titled, serves as an example of how AI-driven technologies can contribute to medical research and education.

ProCAncer-I organised the 4th Dissemination Event of the project at the ECR 2025 held in Vienna, Austria, February 25-26, 2025. During the congress, ProCAncer-I organised a Dedicated Session on the project on the 26th of February 2025, at 15.00-16.00, with the title...

Prostate cancer can vary greatly in how aggressive it is, and knowing this in advance helps doctors decide the best course of treatment. Magnetic resonance imaging (MRI) is often used to detect prostate cancer, but figuring out just how aggressive the cancer is...

ProCAncer-I will organise a Dedicated Session on the project during the European Congress of Radiology 2025 on the 26th of February 2025, at 15.00-16.00, with the title "ProCAncer-I: an AI platform integrating multiparametric MRI and AI models" where we will present...